Fighting to Preserve the Benefits of the 340B Program
HRSA Administrator Thomas J. Engels Issues Dear Colleague Letter to RWCs HRSA Administrator Thomas J. Engels issued a letter to Ryan White Clinic HIV/AIDS Program awardees and stakeholders on April 7, 2025. …
On December 20, 2024, drugmakers Amgen Inc. (Amgen), Eli Lilly and Company (Eli Lilly), and UCB, Inc. (UCB), sued HHS, alleging that HHS has not fulfilled its obligations to oversee…
To close out the year, two federal judges issued conflicting opinions regarding the likelihood of success in challenges to state 340B contract pharmacy laws. In the first major siding with…
On December 16, Sanofi informed HRSA that it will pause the implementation of its rebate model, termed a “340B credit model.” The same day, Sanofi filed a lawsuit in the…
On December 13th, the Health Resources and Services Administration (HRSA) issued a letter to Sanofi calling for the manufacturer to cease implementation of its rebate model, which Sanofi terms a…
Bristol-Myers Squibb Sues HHS To Implement 340B Rebate Model On November 26, 2024, Bristol-Myers Squibb (BMS) filed a lawsuit against HRSA in the D.C. District Court to defend its proposed…
11/19/2024 – Third Lawsuit Is Filed Against HRSA for Blocking the Rebate Model On November 14, 2024, Eli Lilly and Company (Lilly) filed a lawsuit against HHS and HRSA in…
11/14/2024 – J&J Sues HHS and HRSA Over HRSA’s Opposition to J&J’s Proposed Rebate Model On November 12, 2024, Johnson and Johnson Health Care System Inc. (J&J) filed a lawsuit…
Yesterday, Johnson & Johnson Health Care System Inc. (J&J) stated in a letter to HRSA that it will halt implementation of its proposed rebate model, which was set to take…
On July 24, 2024, two hospital-covered entities sued the Health Resources and Services Administration (“HRSA”), arguing that HRSA’s approval of J&J’s 340B audit request against them was unlawful and premature. The…